Insulin aspart - Biologic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for insulin aspart
Tradenames: | 2 |
Patents: | 18 |
Applicants: | 1 |
BLAs: | 4 |
Suppliers: see list | 4 |
Recent Clinical Trials: | See clinical trials for insulin aspart |
Drug Prices: | Drug price information for insulin aspart |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for insulin aspart |
Recent Clinical Trials for insulin aspart
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Amphastar Pharmaceuticals, Inc. | Phase 2/Phase 3 |
Defymed | N/A |
McGill University Health Centre/Research Institute of the McGill University Health Centre | N/A |
Recent Litigation for insulin aspart
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
Novo Nordisk Inc. v. Alvogen, Inc. | 2022-03-03 |
Novo Nordisk Inc. v. Zydus Worldwide DMCC | 2022-03-03 |
Novo Nordisk Inc. v. Aurobindo Pharma USA, Inc. | 2022-03-03 |
Pharmacology for insulin aspart
Established Pharmacologic Class | Insulin Analog |
Chemical Structure | Insulin |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for insulin aspart Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for insulin aspart Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | See Plans and Pricing | 2014-04-08 | Company disclosures |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | See Plans and Pricing | 2014-05-06 | Company disclosures |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | See Plans and Pricing | 2014-12-02 | Company disclosures |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for insulin aspart Derived from Patent Text Search
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | See Plans and Pricing | 2025-05-23 | Patent claims search |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | See Plans and Pricing | 2033-03-11 | Patent claims search |
Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | See Plans and Pricing | 2034-12-01 | Patent claims search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for insulin aspart
Country | Patent Number | Estimated Expiration |
---|---|---|
Germany | 69900026 | See Plans and Pricing |
Japan | 4698677 | See Plans and Pricing |
South Korea | 20030020299 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for insulin aspart
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
99C0044 | Belgium | See Plans and Pricing | PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615 |
SPC/GB00/027 | United Kingdom | See Plans and Pricing | PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801 |
CA 2005 00046 | Denmark | See Plans and Pricing | PRODUCT NAME: OPLOSELIGT INSULIN ASPART / PROTAMINKRYSTALLERET INSULIN ASPART 100E/ML I FORHOLDET 50/50 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.